Objective: the experiment will implement different treatment plans for patients with moderate and severe bronchial asthma, and further compare the clinical efficacy of budesonide and formoterol powder inhalation and b...Objective: the experiment will implement different treatment plans for patients with moderate and severe bronchial asthma, and further compare the clinical efficacy of budesonide and formoterol powder inhalation and budesonide suspension atomization inhalation. Methods: 100 patients with moderate to severe bronchial asthma admitted to our hospital were randomly selected as the subjects of this study. The diagnosis and treatment time range was from July 2020 to August 2021, and they were divided into groups by random design. The control group received budesonide suspension inhalation, while the observation group received budesonide formoterol powder inhalation, and the situation after four weeks of treatment was compared. Results: from the perspective of nursing quality, the lung function indexes of patients in the observation group were better than those in the control group. After treatment, FEV1 and FEV1/FVC in the observation group were (1.69±0.26) L and (65.77±0.28) %, respectively, while those in the control group were (1.13±0.19) L and (56.92±0.17) %. The comparison was statistically significant (P < 0.05). At the same time, the negative rate of bronchial dilation test in the observation group was higher than that in the control group (76.0% and 56.0%, respectively), and the difference was statistically significant. In addition, we compared the asthma control scores of patients before and after treatment, and the scores of the observation group were more advantageous after treatment, indicating that asthma symptoms were better controlled. Finally, the incidence of adverse reactions in patients was compared. There was no significant difference between the two groups, and both groups had safety guarantee. Conclusion: inhalation of Budesonide formoterol powder in the treatment of moderate and severe bronchial asthma has good efficacy, can improve the lung function index of patients, strengthen the control of asthma symptoms, and has the value of clinical promotion.展开更多
文摘Objective: the experiment will implement different treatment plans for patients with moderate and severe bronchial asthma, and further compare the clinical efficacy of budesonide and formoterol powder inhalation and budesonide suspension atomization inhalation. Methods: 100 patients with moderate to severe bronchial asthma admitted to our hospital were randomly selected as the subjects of this study. The diagnosis and treatment time range was from July 2020 to August 2021, and they were divided into groups by random design. The control group received budesonide suspension inhalation, while the observation group received budesonide formoterol powder inhalation, and the situation after four weeks of treatment was compared. Results: from the perspective of nursing quality, the lung function indexes of patients in the observation group were better than those in the control group. After treatment, FEV1 and FEV1/FVC in the observation group were (1.69±0.26) L and (65.77±0.28) %, respectively, while those in the control group were (1.13±0.19) L and (56.92±0.17) %. The comparison was statistically significant (P < 0.05). At the same time, the negative rate of bronchial dilation test in the observation group was higher than that in the control group (76.0% and 56.0%, respectively), and the difference was statistically significant. In addition, we compared the asthma control scores of patients before and after treatment, and the scores of the observation group were more advantageous after treatment, indicating that asthma symptoms were better controlled. Finally, the incidence of adverse reactions in patients was compared. There was no significant difference between the two groups, and both groups had safety guarantee. Conclusion: inhalation of Budesonide formoterol powder in the treatment of moderate and severe bronchial asthma has good efficacy, can improve the lung function index of patients, strengthen the control of asthma symptoms, and has the value of clinical promotion.
